UNITED STATES ~~SECURITIES~~ ~~AND EXCHANGE COMMISSION~~

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER ~~PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934~~

~~For~~PURSUANT ~~the~~TO ~~month~~RULE of13a-16 ~~May~~OR 15d-16 ~~2024~~

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2024

Commission File Number 001-35463

Taro Pharmaceutical Industries Ltd.

(Translation of registrant’s name into English)

14 Hakitor Street, Haifa Bay 2624761, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x ☒ Form 40-F ☐ ¨

CONTENTS

~~Results~~Closing of ~~Shareholder~~Acquisition ~~Vote~~

On January 17, 2024, Taro Pharmaceutical Industries Ltd. (“Taro” or the “Company”) announced it had entered into a merger agreement with Sun Pharmaceutical Industries Ltd. (“Sun Pharma”). OnThe ~~May 22, 2024, at an Extraordinary General Meeting and an Ordinary Class Meeting, the Company’s shareholders voted on the proposed~~ transaction, ~~which~~ was described in the Company’s Proxy Statement dated April 15, 2024, which was most recently attached as Exhibit (a)(3)(i) to Amendment No. 6 5 to the Schedule 13E-3 filed by Taro with the Securities and Exchange Commission on May 14 23, 2024 (as amended from time to time, the “Proxy Statement”). Capitalized terms used herein without definition have the meanings ascribed to them in the Proxy Statement.

The ~~merger~~Merger ~~proposal~~became effective on June 24, ~~along~~2024 ~~with~~(such ~~the~~effective ~~results~~time of the ~~voting~~Merger, isthe ~~provided~~“Effective Time”). As a result of the Merger, the ~~below:~~Company became a private company and an indirect wholly-owned subsidiary of Sun Pharma.

ToAt ~~approve and adopt~~ the ~~Agreement~~Effective ~~of Merger~~Time, ~~dated~~all ~~January~~of ~~17, 2024, by and among~~ the Company,’s ~~Sun~~outstanding Ordinary ~~Pharma,~~Shares ~~Alkaloida~~immediately ~~Chemical~~prior ~~Company~~to ~~ZRT.~~the ~~(f/k/a~~Effective ~~Alkaloida~~Time, ~~Chemical~~other ~~Company~~than ~~Exclusive~~any ~~Group~~shares ~~Limited),~~held ~~The~~by ~~Taro Development Corporation,~~ Sun Pharma ~~Holdings,~~or ~~and~~its ~~Libra Merger Ltd.~~affiliates, ~~the~~were ~~merger~~canceled ofin ~~Merger~~exchange ~~Sub~~for ~~with and into~~ the ~~Company~~right ~~pursuant~~ to ~~the Merger~~receive ~~Agreement~~US$43.00 ~~and~~per ~~the~~Ordinary ~~other~~Share ~~transactions~~in ~~contemplated~~cash bywithout ~~the Merger Agreement~~interest.

AtAs ~~the~~a ~~Extraordinary~~result ~~General~~of ~~Meeting~~the ~~and~~Merger, the Company’s Ordinary ~~Class~~Shares ~~Meeting,~~ceased ~~each of~~to ~~which~~trade ~~was~~on ~~duly~~the ~~convened~~New York Stock Exchange (“NYSE”) prior to ~~approve~~market open on June 24, 2024. On June 24, 2024, NYSE filed an application on Form 25 with the ~~Merger~~Securities and atExchange ~~which~~Commission (the ~~requisite~~“SEC”) ~~quorum~~to withdraw registration of ~~three~~Taro’s Ordinary Shares under the Securities Exchange Act of 1934 (the “Exchange Act”). The deregistration will become effective 90 days after the filing of Form 25, or ~~more~~such ~~shareholders~~shorter ~~who~~period ~~hold~~as atmay ~~least~~be ~~one-third~~determined by the SEC. The Company intends to suspend its remaining reporting obligations under the Exchange Act by filing a Form 15 with the SEC approximately 10 days following the filing of the ~~total~~Form ~~number~~25. The Company’s reporting obligations under the Exchange Act will be suspended immediately as of ~~votes~~the infiling date of the ~~Company~~Form ~~was~~15 ~~present,~~and will terminate once the ~~merger~~deregistration ~~proposal~~becomes ~~was:~~effective.

I.On ~~Approved~~June 24, by2024, ~~the~~Sun ~~affirmative~~Pharma ~~vote~~issued ofa ~~the~~press ~~holders~~release ofannouncing ~~at least 75% of~~ the ~~voting~~consummation ~~power~~ of the Merger. ~~Company~~A ~~present~~copy ~~(in person or by proxy) and voting on such resolution, including at least a majority~~ of the ~~voting~~press ~~power~~release ~~held~~is byfurnished ~~holders~~herewith ~~other~~as ~~than~~Exhibit ~~Sun~~99.1. ~~Pharma and its affiliates, their relatives, persons voting on their behalf or any other holders having a personal interest in the Merger, present (in person or by proxy) and voting thereon;~~

II. Approved by the affirmative vote of the holders of at least 75% of the Company Ordinary Shares present (in person or by proxy) and voting on such resolution at the ordinary class meeting; and

III. Approved by the affirmative vote of the holders of at least 75% of the Company Founder Shares present (in person or by proxy) and voting on such resolution at the founders class meeting.

The Company issued a press release jointly with Sun Pharma relating to the meeting results on May 23, 2024. A copy of the joint press release is furnished herewith as Exhibit 99.1.

Exhibits

Exhibit No.		Description
99.1		Press Release, dated ~~May~~June 2324, 2024

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: ~~May 23~~June 24, 2024

TARO PHARMACEUTICAL INDUSTRIES LTD. By: /s/ Uday Baldota Name: Uday Baldota Title: Chief Executive Officer and Director

By: /s/ Uday Baldota Name: Uday Baldota Title: Chief Executive Officer and Director

Filing Compare · TARO PHARMACEUTICAL INDUSTRIES LTD